Company Description
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals.
It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.
The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations.
Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
| Country | United States |
| Founded | 1954 |
| IPO Date | Sep 20, 2018 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 9,800 |
| CEO | Jeffrey Simmons |
Contact Details
Address: 2500 Innovation Way Greenfield, Indiana 46140 United States | |
| Phone | 877 352 6261 |
| Website | elanco.com |
Stock Details
| Ticker Symbol | ELAN |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001739104 |
| CUSIP Number | 28414H103 |
| ISIN Number | US28414H1032 |
| Employer ID | 82-5497352 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jeffrey N. Simmons | President, Chief Executive Officer and Director |
| Todd S. Young J.D. | Executive Vice President and Chief Financial Officer |
| Dr. Ramiro Martin Cabral | Executive Vice President of Elanco International |
| Dr. Ellen de Brabander Ph.D. | Executive Vice President of Research, Development and Regulatory Affairs |
| Timothy J. Bettington | Executive Vice President of Corporate Strategy and Market Development |
| James M. Meer | Senior Vice President and Chief Accounting Officer |
| Chris Keeley | Senior Vice President and Chief Information Officer |
| David S. Kinard | Executive Vice President of Human Resources, Corporate Communications and Administration |
| Katy Grissom | Head of Investor Relations |
| Shiv O'Neill | Executive Vice President, General Counsel and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 12, 2024 | 8-K | Current Report |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Oct 16, 2024 | 8-K | Current Report |
| Aug 13, 2024 | 8-K | Current Report |
| Aug 8, 2024 | 10-Q | Quarterly Report |
| Aug 8, 2024 | 8-K | Current Report |
| Jul 9, 2024 | 8-K | Current Report |
| Jul 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jul 3, 2024 | 8-K | Current Report |